Genotypic and phenotypic features of de novo and acquired resistance to cancer therapies.

被引：0
|
作者：
Dancey, Janet E. [1 ]
机构：
[1] Ontario Inst Canc Res, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-SY03-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY0301
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
    Harrold, Emily
    Keane, Fergus
    Sinopoli, Jenna Cohen
    Diaz, Luis A.
    Cercek, Andrea
    Yaeger, Rona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 190 - 190
  • [32] Changes in cellular metabolism associated with acquired resistance to endocrine therapies in breast cancer
    Shahajan, Ayesha N.
    Facey, Caroline O. B.
    Cook, Katherine
    Cheema, Amrita
    Hickman, Edward
    Iyer, Harini
    Hu, Rong
    Zwart, Alan
    Johnson, Michael
    Clarke, Robert
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2011, 28 : S32 - S32
  • [33] A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer
    Johnson, Neil
    Speirs, Valerie
    Curtin, Nicola J.
    Hall, Andrew G.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 111 (01) : 55 - 63
  • [34] A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer
    Neil Johnson
    Valerie Speirs
    Nicola J. Curtin
    Andrew G. Hall
    Breast Cancer Research and Treatment, 2008, 111 : 55 - 63
  • [35] EGFR-Mutant NSCLC With de novo or Acquired Squamous Histology: Molecular Features and Clinical Outcomes
    Meador, C.
    Cobb, R.
    Hung, Y.
    Banwait, M.
    Piper-Vallillo, A.
    Muzikansky, A.
    Hata, A.
    Sequist, L. V.
    Piotrowska, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S932 - S933
  • [36] Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
    Jayappa, Kallesh D.
    Portell, Craig A.
    Gordon, Vicki L.
    Capaldo, Brian J.
    Bekiranov, Stefan
    Axelrod, Mark J.
    Brett, L. Kyle
    Wulfkuhle, Julia D.
    Gallagher, Rosa I.
    Petricoin, Emanuel F.
    Bender, Timothy P.
    Williams, Michael E.
    Weber, Michael J.
    BLOOD ADVANCES, 2017, 1 (14) : 933 - 946
  • [37] Soluble agonists in the in vivo macroenvironment generate phenotypic de novo resistance to BTK/Bcl-2 targeted therapies in diverse B-cell malignancies.
    Jayappa, Kallesh D.
    Portell, Craig A.
    Gordon, Vicki L.
    Bender, Timothy P.
    Williams, Michael E.
    Weber, Michael J.
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 39 - 40
  • [38] De novo drug resistance associated with cell adhesion protects myeloma cells from melphalan induced cytotoxicity: Comparison of de novo and acquired mechanisms of melphalan resistance in myeloma cells.
    Painter, J
    Hazlehurst, LA
    Shain, KS
    Saporta, S
    Boulware, D
    Dalton, WS
    BLOOD, 2001, 98 (11) : 715A - 715A
  • [39] Phenotypic and Genotypic Investigation of Resistance and Virulence Features of Methicillin Resistant Staphylococcus Aureus Strains Isolated from Hospitalized Patients
    Nicoleta, Merezeanu
    Gheorghe, Irina
    Popa, Marcela
    Lazar, Veronica
    Banu, Otilia
    Bolocan, Alexandra
    Grigore, Raluca
    Bertesteanu, Serban Vifor
    Octav, Pantea
    ROMANIAN BIOTECHNOLOGICAL LETTERS, 2016, 21 (03): : 11591 - 11598
  • [40] PI3K/AKT activation in de novo and acquired resistance to ibrutinib in lymphoid malignancies
    Li, Yue
    Kapoor, Isha
    Zhu, Huayuan
    Hill, Brian T.
    Xu, Wei
    Almasan, Alex
    CANCER RESEARCH, 2018, 78 (13)
12345